Details for Patent: 6,489,329

Title:	Pharmaceutical compositions for the treatment of rhinitis
Abstract:	A pharmaceutical composition comprising a therapeutically effective amount of a mixture consisting essentially of (i) pseudoephedrine, an individual optical isomer or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivatives, an individual optical isomer or a pharmaceutically acceptable salt thereof.
Inventor(s):	van de Venne; Herman (Lasne, BE), Martin; Jean-Pierre (Montigny-Le-Tilleul, BE)
Assignee:	UCB S.A. (Brussels, BE)
Filing Date:	Apr 20, 2001
Application Number:	09/838,190
Claims:	1. A pharmaceutical composition which comprises a therapeutically effective amount of a mixture consisting essentially of i) about 70 to about 99 percent by weight of a compound selected from pseudoephedrine, an individual optical isomer thereof, or a pharmaceutically acceptable salt thereof, and ii) about 1 to about 30 percent by weight of a compound selected from the racemate of 2-[2-[4[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, a levorotary or dextrotatory enantiomer thereof, or a pharmaceutically acceptable salt thereof. 2. The pharmaceutical composition according to claim 1, wherein said composition consists essentially of about 3 to about 15 percent by weight of said compound (ii) and about 85 to about 97 percent by weight of said compound (i). 3. The pharmaceutical composition according to claim 1, which includes at least one pharmaceutically acceptable carrier or excipient. 4. The pharmaceutical composition according to claim 1, in the form of a dose containing about 15 to about 300 mg of the mixture of said compounds (i) and (ii). 5. The pharmaceutical composition according to claim 3, in the form of a coated tablet, wherein the tablet coating comprises the effective amount of said compound (ii) and the tablet core comprises the effective amount of said compound (i) and a swellable hydropholic polymer, and wherein the tablet coating and the tablet core further comprise a pharmaceutically acceptable carrier or excipient. 6. The pharmaceutical composition according to claim 3, in the form of a capsule.